NCT05899816: An ongoing trial by Amgen
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05899816 |
|---|---|
| Title | A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 7, 2023 |
| Completion date | Aug. 26, 2024 |
| Required reporting date | Aug. 26, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |